Volume 92, Issue 7 pp. E481-E485
Valvular and Structural Heart Diseases (E-only Article)

Valve-in-valve-in-valve: Balloon expandable transcatheter heart valve in failing self-expandable transcatheter heart valve in deteriorated surgical bioprosthesis

Andreas Schaefer MD, MHBA

Corresponding Author

Andreas Schaefer MD, MHBA

Department of Cardiovascular Surgery, University Heart Center Hamburg, Martinistraße 52, D-20246 Hamburg, Germany

Correspondence

Andreas Schaefer, MD, MHBA, University Heart Center Hamburg, Martinistraße 52, D-20246 Hamburg, Germany.

Email: [email protected]

Search for more papers by this author
Florian Deuschl MD

Florian Deuschl MD

Department of General and Interventional Cardiology, University Heart Center Hamburg, Martinistraße 52, D-20246 Hamburg, Germany

Search for more papers by this author
Lenard Conradi MD

Lenard Conradi MD

Department of Cardiovascular Surgery, University Heart Center Hamburg, Martinistraße 52, D-20246 Hamburg, Germany

Search for more papers by this author
Ulrich Schäfer MD

Ulrich Schäfer MD

Department of General and Interventional Cardiology, University Heart Center Hamburg, Martinistraße 52, D-20246 Hamburg, Germany

Search for more papers by this author
First published: 09 September 2018
Citations: 4

Abstract

Valve-in-valve (ViV) procedures for failing bioprostheses carry a certain risk for device malfunction. We herein report a case of a failing Evolut R in a deteriorated Mitroflow, treated with a Sapien 3.

An 81 year old female patient received surgical aortic valve replacement and was treated by ViV due to deterioration. Three years later, echocardiography revealed a pressure gradient of peak/mean 105/63 mmHg. Subsequently, a second ViV procedure with initial intentional rupture of the bioprosthetic stent was performed. Immediate stent recoil of the Evolut R prompted implantation of a Sapien 3. In 30-day follow-up, mean pressure gradient of 30 mmHg and nearly complete symptom relief was documented.

Fracture of a surgical bioprosthetic stent is feasible in a ViV configuration. Supra-annular placement of a balloon-expandable THV as ViV-in-valve is feasible with suboptimal hemodynamic results in this case. Risk of re-do surgery should be weighted against anticipated hemodynamic and clinical results.

CONFLICT OF INTEREST

U. Schaefer is a proctor for Medtronic, is a consultant to Medtronic, and has received lecture fees from Medtronic. L. Conradi is a proctor for Medtronic and proctor, advisory board member and consultant for Edwards Lifesciences. All other authors have nothing to disclose regarding this work.

The full text of this article hosted at iucr.org is unavailable due to technical difficulties.